Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Study design

XX Xiangwei Xu
RL Ruya Li
PZ Peizhen Zhu
PZ Penghai Zhang
JC Jun Chen
YL Yongsheng Lin
YC Yinqiao Chen
request Request a Protocol
ask Ask a question
Favorite

Clinical data included sex, age, marital status, smoking status, type of medical insurance, pathological type, clinical stage, metastatic sites, distal metastasis, performance status (PS) score, first-line chemotherapy drugs, antiangiogenic drugs, therapeutic effects evaluated after first-line chemotherapy, MT regimen (targeted and anti-angiogenic drugs, chemotherapy with one drug), complications during chemotherapy, and follow-up information. Patients with stable or responsive stage IIIB/IV NSCLC were also classified into the MT and non-MT groups according to whether they received MT or not after 4–6 cycles of first-line chemotherapy.

By reviewing the hospital clinical records, as well as messages and telephone follow-up, tumor response and complications were analyzed until the end of December 31, 2019. The endpoints comprised the PFS calculated from the first dose until disease progression, and OS calculated from the initial diagnosis to death or the end of follow-up, which are expressed on a monthly basis.

Copyright and License information: The Author(s) ©2021
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A